Invitae (NYSE:NVTA) Now Covered by StockNews.com

StockNews.com started coverage on shares of Invitae (NYSE:NVTA) in a research note issued to investors on Tuesday morning. The firm issued a hold rating on the medical research company’s stock.

Invitae Price Performance

NYSE NVTA opened at $0.00 on Tuesday. The company has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.34. Invitae has a 12-month low of $0.02 and a 12-month high of $0.02. The stock has a market capitalization of $267,010.00, a PE ratio of 0.00 and a beta of 1.59.

Institutional Trading of Invitae

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Invitae in the third quarter worth $29,000. Janney Montgomery Scott LLC raised its stake in Invitae by 404.6% during the 3rd quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 50,600 shares during the last quarter. Financial Gravity Asset Management Inc. raised its stake in Invitae by 1,799.5% during the 3rd quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 70,037 shares during the last quarter. Pathstone Family Office LLC raised its stake in Invitae by 94.2% during the 3rd quarter. Pathstone Family Office LLC now owns 157,972 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 76,639 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in Invitae by 24.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 224,642 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 43,642 shares during the last quarter. 61.28% of the stock is currently owned by institutional investors and hedge funds.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.